These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 38360997)
1. VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation. Wang Z; Yan M; Ye L; Zhou Q; Duan Y; Jiang H; Wang L; Ouyang Y; Zhang H; Shen Y; Ji G; Chen X; Tian Q; Xiao L; Wu Q; Meng Y; Liu G; Ma L; Lei B; Lu Z; Xu D EMBO J; 2024 Mar; 43(6):931-955. PubMed ID: 38360997 [TBL] [Abstract][Full Text] [Related]
2. von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas. Yi Y; Mikhaylova O; Mamedova A; Bastola P; Biesiada J; Alshaikh E; Levin L; Sheridan RM; Meller J; Czyzyk-Krzeska MF Clin Cancer Res; 2010 Nov; 16(21):5142-52. PubMed ID: 20978146 [TBL] [Abstract][Full Text] [Related]
3. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition. Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960 [TBL] [Abstract][Full Text] [Related]
4. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364 [TBL] [Abstract][Full Text] [Related]
5. TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling. Zhang X; Li S; He J; Jin Y; Zhang R; Dong W; Lin M; Yang Y; Tian T; Zhou Y; Xu Y; Lei QY; Zhang J; Zhang Q; Xu Y; Lv L Cancer Res; 2022 Jun; 82(11):2097-2109. PubMed ID: 35176127 [TBL] [Abstract][Full Text] [Related]
7. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status. Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870 [TBL] [Abstract][Full Text] [Related]
8. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation. Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971 [TBL] [Abstract][Full Text] [Related]
9. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Mikhaylova O; Stratton Y; Hall D; Kellner E; Ehmer B; Drew AF; Gallo CA; Plas DR; Biesiada J; Meller J; Czyzyk-Krzeska MF Cancer Cell; 2012 Apr; 21(4):532-46. PubMed ID: 22516261 [TBL] [Abstract][Full Text] [Related]
10. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma. Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846 [TBL] [Abstract][Full Text] [Related]
11. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene]. Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350 [TBL] [Abstract][Full Text] [Related]
12. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma. Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867 [TBL] [Abstract][Full Text] [Related]
13. The m Xiao Y; Thakkar KN; Zhao H; Broughton J; Li Y; Seoane JA; Diep AN; Metzner TJ; von Eyben R; Dill DL; Brooks JD; Curtis C; Leppert JT; Ye J; Peehl DM; Giaccia AJ; Sinha S; Rankin EB Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21441-21449. PubMed ID: 32817424 [TBL] [Abstract][Full Text] [Related]
14. Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma. Guo K; Wei Y; Wang Z; Zhang X; Zhang X; Liu X; Wu W; Wu Z; Zhang L; Cui CP Cell Death Dis; 2022 Feb; 13(2):97. PubMed ID: 35110537 [TBL] [Abstract][Full Text] [Related]
15. Prolyl Hydroxylase 3 Knockdown Accelerates Zacharias NM; Wang L; Maity T; Li L; Millward SW; Karam JA; Wood CG; Navai N Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799686 [TBL] [Abstract][Full Text] [Related]
16. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348 [TBL] [Abstract][Full Text] [Related]
17. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α. Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234 [TBL] [Abstract][Full Text] [Related]
18. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α. Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772 [TBL] [Abstract][Full Text] [Related]
19. The von Hippel-Lindau tumor suppressor protein and Egl-9-Type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress. Mikhaylova O; Ignacak ML; Barankiewicz TJ; Harbaugh SV; Yi Y; Maxwell PH; Schneider M; Van Geyte K; Carmeliet P; Revelo MP; Wyder M; Greis KD; Meller J; Czyzyk-Krzeska MF Mol Cell Biol; 2008 Apr; 28(8):2701-17. PubMed ID: 18285459 [TBL] [Abstract][Full Text] [Related]
20. Blockade of β2-Adrenergic Receptor Reduces Inflammation and Oxidative Stress in Clear Cell Renal Cell Carcinoma. Albiñana V; Recio-Poveda L; González-Peramato P; Martinez-Piñeiro L; Botella LM; Cuesta AM Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163250 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]